Not out of possibility, but out of necessity
Greece emerged as the EU’s poster child in the fight against Covid-19 during the first few months of the pandemic. Its approach, while effective, is not beyond reproach.
With the circulation of the Coronavirus, governments are trying to restrict the movement of people.
The European Union (EU) budget is about one percent of the Gross Domestic Product (GDP) of all Member States amounting to about €240 per annum, per citizen. The EU budget redistributes more than €150 billion annually.
The ongoing COVID-19 pandemic is arguably one of the biggest crises of modern times. The conflict between the search for a vaccine, and the artificial scarcity created by patent law, has created a catch-22 situation. How will patent law apply to a vaccine under these circumstances?
During the European Council this week all eyes are, again, on the negotiations for the future European Union (EU) budget. Analysts tended to focus mainly on two things.
Several pharmaceutical companies all around the world, including in the European Union (EU), have been racing to find a treatment for the virus. Since these may be subject to patent rights, government intervention may be needed.
How do we guarantee access to COVID-19 vaccines and therapies, and secure health-related human rights for all? We’ve heard a string of promises in the race for new vaccines and therapies.
It feels sometimes as if the whole world of science is working exclusively on finding a cure for COVID-19.